{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-309544","form_type":"8-K","ticker":null,"cik":"0001008848","company_name":"Acorda Therapeutics, Inc.","filed_at":"2022-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.212999+00:00","generated_at":"2026-06-21T00:39:07.343231+00:00","sec_items":["3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acorda Therapeutics faces Nasdaq delisting for bid price noncompliance; hearing requested","bullets":["Nasdaq notified Acorda that common stock will be delisted on Dec 29, 2022 for failing to maintain $1 minimum bid price for 30 consecutive business days.","Company had 180-day compliance period that ended Dec 19, 2022; did not regain compliance.","Acorda will request a hearing within 7 days, which automatically stays delisting pending Panel decision.","Hearings Panel may grant extension to regain compliance until June 17, 2023; company plans to present plan.","Stockholders approved reverse stock split (1:2 to 1:20) in Nov 2022; CEO prefers organic growth but split is an option."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-309544","json":"https://secwatch.observer/filing/0001193125-22-309544.json","markdown":"https://secwatch.observer/filing/0001193125-22-309544.md","text":"https://secwatch.observer/filing/0001193125-22-309544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1008848/000119312522309544/0001193125-22-309544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1008848/000119312522309544/d368917d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T00:39:07.343231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec6649459b2cba3cab2db8a894866b50d54c5bc7","claim":"Acorda Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"December 20, 2022, the Company received a written notice from the Staff (the “ Staff Determination ”) that that the Company’s common stock would be delisted from the Nasdaq Global Select Market and suspended at the opening of business on December 29, 2022, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Panel ”). The Company intends to request a hearing before the Panel (the “ Hearing ”) to appeal the Staff Determination. This Hearing request will automatically stay Nasdaq’s delisting of the Company’s common stock pending the Panel’s decision. The Company e","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1008848/000119312522309544/0001193125-22-309544-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}